pharma news today glp-1 obesity drugs today A $60 billion industry just found its next growth lever. ๐ With the expiry of a key patent on March 20, 2026, Indian majors are launching generic weight-loss and diabetes ๐ Millions More Americans Gain
Description
The Wnt Signaling Pathway Effector TCF7L2 Controls Gut and Brain Proglucagon Gene Expression and Glucose Homeostasis
The absence of a control group precludes definitive conclusions on causality between GLP-1 receptor agonist therapy and observed outcomes, and residual confounding cannot be excluded In conclusion, arGLP-1 represent a valuable addition to the therapeutic arsenal for managing IWL or WR after BS
This means using a syringe or auto-injector to deliver the medication under the skin, typically in the abdomen or thigh
Steatotic liver disease in pediatric obesity and increased risk for youth-onset type 2 diabetes
The event ended abruptly when an attendee in the Oval Office collapsed
Importantly, a substantial number of patients had multiple reasons noted for stopping (21%), underscoring the complexity of real-world medication use and the challenges patients face when using these therapies
